Overview
Tissue Regeneration Therapeutics (TRT) is a start-up company that is developing umbilical stem cell-based treatments. TRT will use the PBDF investment to conduct proteomic and transcriptomic analyses to further understand their mesenchymal stem cells. These studies will provide valuable information needed for regulatory approval to conduct human clinical trials and further differentiate their product from those of competitors.